

Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis

K Nouso^{*1}, YM Ito², K Kuwaki³, Y Kobayashi³, S Nakamura³, Y Ohashi² and K Yamamoto³

¹Department of Internal Medicine, Hiroshima City Hospital, Hiroshima, Japan; ²Department of Biostatistics, School of Public Health, The University of Tokyo, Tokyo, Japan; ³Department of Medicine and Medical Sciences, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan

The aim of this study is to elucidate the prognostic factors and the treatment effect on survival in hepatocellular carcinoma (HCC) patients with Child C cirrhosis. Out of 3330 newly discovered HCC patients, 157 consecutive HCC individuals with Child C cirrhosis were enrolled. The prognostic factors were examined by Cox proportional hazards regression analysis and their survival was compared by propensity score-matched analysis. Multivariate analysis revealed that high serum bilirubin ($> 3 \text{ mg dl}^{-1}$), the presence of uncontrollable ascites, and a high platelet count ($> 8 \times 10^4 \text{ mm}^{-3}$), so-called background liver factors, as well as multiple tumours, large tumours ($> 3 \text{ cm}$), high alpha-fetoprotein ($> 400 \text{ ng ml}^{-1}$), and the presence of portal vein thrombus, so-called tumour factors, were factors of poor prognosis. While transcatheter arterial chemoembolisation (TACE) was a factor of good prognosis (relative risk = 0.50, 95%CI = 0.27–0.89, $P = 0.019$), local ablation therapy and transcatheter arterial chemoinfusion (TAI) were not significant prognostic factors. The survival of patients who received TACE was superior to matched patients without active treatment ($P = 0.009$); however, we did not observe survival benefit after local ablation therapy or TAI. These results suggested that tumour factors as well as background liver factors are prognostic factors of HCC even in patients with Child C cirrhosis, and selective use of TACE in these patients provides survival benefit.

British Journal of Cancer (2008) 98, 1161–1165. doi:10.1038/sj.bjc.6604282 www.bjcancer.com

Published online 18 March 2008

© 2008 Cancer Research UK

Keywords: decompensated cirrhosis; prognostic factors; hepatocellular carcinoma; therapy

Hepatocellular carcinoma (HCC) is the fifth cause of death by cancer worldwide (Parkin, 2001). Many symptomatic HCCs are diagnosed in advanced stage and cannot be treated, so the prognosis is generally poor (Wong *et al*, 2000; Bruix and Llovet, 2002). By the accumulation of knowledge of the risk factors and the prevalence of HCC surveillance, the proportion of HCC diagnosed in early stage and that can be treated by local ablation therapies or surgery has increased (Bolondi, 2003; Adams *et al*, 2004; Trevisani *et al*, 2004).

In spite of the early detection of HCC, many patients die of complications of severe cirrhosis without any active treatment (Ikai *et al*, 2007). According to the algorithms of the treatment of HCC recommended by groups in Europe and Japan (Bruix *et al*, 2001; Llovet, 2005; Makuuchi and Kokudo, 2006), HCC patient with Child C cirrhosis (Pugh *et al*, 1973) is a candidate for liver transplantation or best supportive care (BSC). However, even though HCC meets the Milan criteria, many patients do not receive liver transplantation because of the shortage of donors or advanced age (United Network for Organ Sharing, 2006). Although there is regional variability, patients diagnosed with HCC in the background of hepatitis C virus infection are usually elderly (Parkin, 2001). In Japan, the mean age of patients is 66.6 years old

(Ikai *et al*, 2007); therefore, a large number of the patients are outside the liver transplantation criteria and receive only BSC.

Local ablation therapies and transcatheter arterial chemoembolisation (TACE) are known to be useful for HCC treatment with preserved liver function (Llovet *et al*, 2003). Nevertheless, these therapies for patients with Child C cirrhosis are not recommended because of reported severe adverse events. However, there is lack of knowledge on prognostic factors on the effectiveness of active treatment, except liver transplantation, in HCC patients with Child C cirrhosis (Llovet, 2005). Therefore, it is very important to identify factors influencing outcomes of cirrhotic patients affected by HCC who cannot be treated by liver transplantation.

In this study, we retrospectively examined the clinical course of HCC patients with Child C cirrhosis and analysed their prognostic factors.

PATIENTS AND METHODS

Patients

Between January 1996 and September 2006 among 3330 consecutive newly diagnosed HCC patients who were admitted to our department and affiliated hospitals, 186 individuals had Child C cirrhosis. Five patients were excluded because of a lack of clinical data, 24 were excluded because they underwent liver transplantation, and the remaining patients ($n = 157$) were enrolled in this

*Correspondence: Dr K Nouso; E-mail: nouso@cc.okayama-u.ac.jp

Received 4 October 2007; revised 24 January 2008; accepted 29 January 2008; published online 18 March 2008

study. Informed consent was obtained from all patients for use of their clinical data. The study protocol conformed to the ethical guidelines of the World Medical Association Declaration of Helsinki, and was approved by the ethical committees of the institutes.

Diagnosis

One hundred and forty-one patients were diagnosed as having HCC by imaging modalities, such as angiography, computed tomography (CT), and magnetic resonance imaging (MRI). Diagnostic criteria for HCC via imaging was based on previous reports of hyperattenuation at the arterial phase, hypoattenuation at the portal phase in dynamic CT (section thickness = 5–8 mm) or MRI, and tumour stain on angiography (Honda *et al*, 1993). The remaining 16 patients with hepatic masses who did not satisfy the above criteria underwent ultrasound (US)-guided fine-needle biopsy with histologically confirmed HCC.

Treatments

As there is no clear evidence that active treatment of HCC improves the survival of patients with Child C cirrhosis, all the patients were informed that the potential treatment benefits were unknown and the risks of the treatments were higher than in patients with Child A/B cirrhosis. We conducted local ablation therapy, TACE, or transcatheter arterial chemoembolisation (TAI) only when patients consented to undergo these interventions. Percutaneous ethanol injection therapy, radiofrequency ablation, and microwave coagulation therapy were performed in 18, 4, and 1 patients, respectively. All HCCs treated by local ablation therapy were less than 3 cm in diameter and less than three tumours, except three single large HCC with diameters between 3.0 and 3.5 cm. There are two major differences of our treatment algorithm for patients with Child C cirrhosis from that for patients with Child A/B cirrhosis. Surgical resection was not chosen and indication for local ablation therapy was stricter. When a tumour protruded from the liver surface, attached to the adjacent organs such as gall bladder, or a tumour was not confirmed well by ultrasonography, local ablation therapies were not performed. The therapies were also avoided when uncontrollable ascites was present. We included transcatheter arterial embolisation (TAE) in the group undergoing TACE, because the number of patients who received TAE was small and no clear difference in the treatment effect was reported in previous studies (Camma *et al*, 2002). Transcatheter arterial chemoembolisation was not chosen principally in cases of severe portal vein tumour thrombus (PVTT). Transcatheter arterial chemoembolisation and TAI were performed supraselectively in the most peripheral accessible feeding artery to avoid irreversible liver failure. When the treatment might cause immediate irreversible liver failure or severe complications, we did not perform any active treatments irrespective of the patients' wishes, except emergency TACE for HCC rupture.

Follow-up

Biochemical liver function tests and US, dynamic CT, or MRI were performed at least every 3 months after the treatment. Re-treatment was performed depending on patients' conditions, tumour stage and background liver function, according to the same clinical indications as for the first intervention.

Statistical analysis

The Kruskal–Wallis test was used to compare the continuous data and the χ^2 test was used to compare categorical data. Cox proportional hazards regression analysis was used to analyse the prognostic factors. Factors exhibiting significant values in

univariate analysis and effect of the treatments were further analysed by multivariate analysis. The propensity score of choosing each treatment was calculated, followed by matching each treatment group and BSC group according to a greedy matching technique (Parsons, 2001). For calculation of the propensity score, following variables (cutoffs) were used: total bilirubin (<2, 2–3, >3, mg per dl), tumour size (<20, 20–30, >30, mm), tumour number (1, >1), PVTT (absent, present). The survival of matched patients was compared by the Kaplan–Meyer method and the differences were evaluated by the log-rank test. SAS (version 9.1.3) and JMP (version 5.0.1) software packages (SAS Institute, Cary, NC, USA) were used for analyses, and $P < 0.05$ was considered significant. Bonferroni correction was used for multiple comparisons of propensity score-matched analyses and $P < 0.05/3$ was considered significant.

RESULTS

Clinical characteristic of the patients

Twenty-three patients (14.7%) were treated by local ablation therapy, 27 (17.2%) by TACE, and 19 (12.1%) by TAI. The remaining patients ($n = 88$, 56.1%) did not receive any of these treatments (BSC group). One- and 3-year survival of patients was 42.6 and 14.0%, respectively.

The characteristics of all patients are reported in Table 1. There was no difference in sex and age among these groups. The positive rate of hepatitis C virus antibody was low (55.7%) in the BSC group. Background liver function (Child–Pugh score) was worse and the tumours were more advanced (tumour size, tumour number, alpha-fetoprotein (AFP), and PVTT) in the BSC group than in other groups. Eighteen patients could be re-treated by local ablation therapies, TAE, or TAI.

Risk factors for survival of HCC patients with Child C cirrhosis

Among 17 parameters and treatment modalities, high bilirubin ($> 3 \text{ mg dl}^{-1}$), the presence of uncontrollable ascites, and a high platelet count ($> 8 \times 10^4 \text{ mm}^{-3}$), so-called background liver factors, as well as multiple tumour number, large tumour ($> 3 \text{ cm}$), high AFP ($> 400 \text{ ng ml}^{-1}$), and the presence of PVTT, so-called tumour factors, were significant risk factors for death in univariate analysis in Table 2. Conversely, TACE and local ablation therapy were associated with better survival. As shown in Table 3, multivariate analysis revealed that all background factors and tumour factors that were significant in univariate analysis were also significant risk factors. Regarding therapies, only TACE was a significant negative risk factor for death by multivariate analysis.

Survival of patients in different therapeutic groups

One-year (3-year) survival of patients receiving local ablation therapy, TACE, TAI, and BSC was 69.1 (41.3), 62.5 (29.8), 43.9 (12.6), and 27.7% (3.8%), respectively ($P < 0.001$, Figure 1). To estimate the effect of treatments, the clinical background of the patients in each group was adjusted by propensity scores, and the survival of treated groups was compared with the BSC group. Numbers of the score-matched pairs were 25, 19, and 19 for TACE vs BSC group, local ablation therapy vs BSC group, and TAI vs BSC group, respectively. One patient in the BSC group for the comparison with TACE group had a main portal vein thrombus. While survival in the TACE group was significantly better than in the BSC group ($P = 0.009$, Figure 2), no differences in survival were observed between the local ablation group and BSC group ($P = 0.782$, Figure 3), and between TAI group and BSC group ($P = 0.237$, Figure 4).

Table 1 Clinical background of 157 patients

	TACE	TAI	Local	BSC	P-value
Patient number	27 (17.2%)	19 (12.1%)	23 (14.7%)	88 (56.1%)	
Sex (male)	21 (77.8%)	15 (79.0%)	16 (69.6%)	64 (72.7%)	0.085
Age (years)	66 (55–70)	65 (60–68)	59 (52–64)	62 (56–70)	0.275
HCVAb (positive)	24 (88.9%)	15 (79.0%)	18 (78.3%)	49 (55.7%)	0.003
HBsAg (positive)	2 (7.4%)	2 (10.5%)	4 (17.4%)	25 (28.4%)	0.061
Total bilirubin (mg per dl)	1.9 (1.2–2.5)	2.4 (2.1–3.1)	2.8 (2.1–3.4)	3.5 (2.2–4.8)	<0.001
Albumin (g per dl)	2.6 (2.5–2.7)	2.5 (2.3–2.9)	2.7 (2.5–3.0)	2.6 (2.2–2.9)	0.213
AST (IU per l)	61 (50–105)	83 (65–111)	72 (50–103)	80 (46–188)	0.426
ALT (IU per l)	41 (35–61)	57 (40–76)	48 (40–68)	44 (36–86)	0.550
Platelet ($\times 10^4 \text{ mm}^{-3}$)	8.8 (5.7–11.6)	7 (5.1–9.7)	5.7 (4.7–7.2)	9.4 (6.1–13.7)	0.004
Prothrombin time (%)	64.2 (50.0–68.9)	61 (55.6–66.3)	54.4 (49.4–62.0)	54.1 (45.0–63.0)	0.012
Creatinine (mg per dl)	0.81 (0.70–0.96)	0.76 (0.66–1.10)	0.77 (0.60–0.90)	0.78 (0.61–1.03)	0.593
Ascites (present)	13 (48.2%)	8 (42.1%)	5 (21.7%)	60 (68.2%)	<0.001
Encephalopathy (present)	12 (44.5%)	9 (43.4%)	8 (34.8%)	40 (45.5%)	0.811
Tumour number (single)	9 (33.3%)	7 (36.8%)	17 (73.9%)	28 (31.8%)	0.002
Tumour size (mm)	38 (23–53)	32 (26–65)	20 (17–29)	51.5 (30–100)	<0.001
AFP (ng per ml)	32 (13–1250)	81 (13–706)	21 (9–106)	188 (26–8660)	0.001
Portal invasion (present)	7 (25.9%)	6 (31.6%)	0 (0%)	49 (55.7%)	<0.001
Child-Pugh score (10/11/12~)	15/11/1	11/6/2	13/7/3	26/23/39	<0.001

Abbreviations: AFP = alpha-fetoprotein; ALT = alanine aminotransferase; AST = aspartate aminotransferase; HBsAg = hepatitis B virus surface-antigen; HCVAb = hepatitis C virus-antibody. All variables are shown in median (interquartile range) unless otherwise noted.

Table 2 Univariate analysis of the prognostic factors of HCC patients with Child C cirrhosis

	RR	95% CI	P-value
Sex (male)	1.16	0.78–1.78	0.457
Age (per 10 years)	1.11	0.91–1.36	0.264
HCVAb (positive)	0.96	0.65–1.44	0.869
HBsAg (positive)	1.21	0.75–1.88	0.404
Total bilirubin ($> 3 \text{ mg dl}^{-1}$)	2.14	1.48–3.09	<0.001
Albumin ($> 3 \text{ g dl}^{-1}$)	1.46	0.94–2.21	0.090
AST ($> 40 \text{ IU l}^{-1}$)	1.04	0.66–1.72	0.843
ALT ($> 40 \text{ IU l}^{-1}$)	1.31	0.90–1.92	0.148
Platelets ($> 8 \times 10^4 \text{ mm}^{-3}$)	2.23	1.52–3.26	<0.001
Prothrombin time ($> 50\%$)	1.24	0.84–1.86	0.275
Creatinine ($> 1 \text{ mg dl}^{-1}$)	1.16	0.74–1.76	0.487
Ascites (uncontrollable)	2.46	1.67–3.66	<0.001
Encephalopathy (present)	0.98	0.67–1.41	0.926
Tumour number (multiple)	2.21	1.49–3.31	<0.001
Tumour size ($> 30 \text{ mm}$)	3.81	2.54–5.83	<0.001
AFP ($> 400 \text{ ng ml}^{-1}$)	2.49	1.69–3.63	<0.001
Portal invasion (present)	3.90	2.64–5.76	<0.001
TACE	0.56	0.33–0.91	0.019
Local ablation	0.42	0.24–0.70	<0.001
TAI	0.97	0.54–1.61	0.915

Abbreviations: TACE = transcatheter arterial chemoembolisation; TAI = transcatheter arterial chemoinfusion. Other abbreviations are as listed in Table 1.

Table 3 Multivariate analysis of the prognostic factors of HCC patients with Child C cirrhosis

	RR	95% CI	P-value
Total bilirubin ($> 3 \text{ mg dl}^{-1}$)	2.94	1.90–4.58	<0.001
Platelets ($> 8 \times 10^4 \text{ mm}^{-3}$)	1.77	1.11–2.84	0.016
Ascites (uncontrollable)	1.80	1.14–2.87	0.010
Tumour number (multiple)	1.67	1.06–2.66	0.025
Tumour size ($> 30 \text{ mm}$)	3.00	1.74–5.24	<0.001
AFP ($> 400 \text{ ng ml}^{-1}$)	1.68	1.05–2.67	0.029
Portal invasion (present)	1.77	1.09–2.85	0.019
TACE	0.50	0.27–0.89	0.019
Local ablation	1.02	0.51–1.96	0.944
TAI	0.64	0.33–1.16	0.152

Abbreviations are as listed in Tables 1 and 2.





Figure 1 Survival of HCC patients with Child C cirrhosis. One-year (3-year) survival of patients receiving local ablation therapy (solid line), TACE (dotted line), transcatheter chemoinfusion (grey line), and BSC (thin line) was 69.1 (41.3), 62.5 (29.8), 43.9 (12.6), and 27.7% (3.8%), respectively ($P < 0.001$).


DISCUSSION

The prognosis of HCC patients with Child C cirrhosis is well known to be poor; however, there is little information about the prognostic factors among patients and the effect of active treatment, except liver transplantation (Llovet, 2005). In this study, we clearly demonstrated that high total bilirubin ($> 3 \text{ mg dl}^{-1}$) and the presence of uncontrollable ascites, categorised as background liver factors, were independent factors for poor prognosis in HCC patients with Child C cirrhosis. In addition, tumour factors such as tumour size ($> 3 \text{ cm}$), tumour number (multiple), AFP ($> 400 \text{ ng ml}^{-1}$), and PVTT were also independent prognostic factors. These factors were quite similar to the reported prognostic factors for HCC, which include chronic hepatitis and Child A or B cirrhosis (Sala *et al*, 2005). High platelet count also correlated with poor prognosis. Platelet is known to decrease according to the advancement of cirrhosis. Therefore, it is possible




Patients at risk	0	250	500	750	1000	1250	1500
TACE	25	17	13	7	4	2	2
BSC	25	7	6	3	1	0	0

Figure 2 Survival of propensity score-matched patients treated by TACE or BSC. The survival of the TACE group (solid line) was significantly better than that of the BSC group (dotted line, $P = 0.009$).



Patients at risk	0	250	500	750	1000	1250	1500
Local	19	15	10	9	7	6	3
BSC	19	11	9	5	3	2	2

Figure 3 Survival of propensity score-matched patients treated by local ablation therapy (Local) or BSC. No differences were observed between the Local group (solid line) and BSC group (dotted line, $P = 0.782$).



Patients at risk	0	250	500	750	1000	1250	1500
TAI	19	10	7	4	2	2	2
BSC	19	4	4	2	0	0	0

Figure 4 Survival of propensity score-matched patients treated by TAI or BSC. No differences were observed between TAI group (solid line) and BSC group (dotted line, $P = 0.237$).

that the liver in patients with high platelet count is not cirrhotic and the liver function is disturbed by very advanced HCC, which can be a reason of poor prognosis. This explanation was strengthened by a result in this study. The size of HCC in patients with high platelet count was significantly larger than that in patients with low platelet count (data not shown).

The contribution of tumour factors to HCC patients with Child C cirrhosis indicated that HCC treatment might prolong survival even though the patients suffered from Child C cirrhosis. The results of multivariate analysis of the treatments and of propensity score-matched survival curves support this hypothesis. The relative risk for patients undergoing TACE was 0.50 and survival of this group was better than that of BSC ($P = 0.009$). Only two patients died within a month and had been treated by TACE because of HCC rupture (data not shown). Although TACE might be an eligible method for the treatment of HCC with Child C cirrhosis, the results do not indicate that TACE is effective in all Child C patients. Transcatheter arterial chemoembolisation was selected for patients without severe portal vein thrombus and with relatively good liver function in this analysed population. The medians of bilirubin and prothrombin time in TACE group were 1.9 mg dl^{-1} and 64.2%, respectively.

While TACE showed a beneficial effect, local ablation therapy did not prolong survival. One possible reason is that the deterioration of liver function to death is much faster than tumour progression. The reported 1-year local recurrence rate of HCC in patients treated by local ablation therapy was low (2–18%) (Lin et al, 2005; Tateishi et al, 2006; Kim et al, 2006b), whereas the 1-year survival rate of Child C patients treated by local ablation therapy was 69.1%, indicating that many patients died without recurrence of HCC. Although no effect of local ablation therapy was observed, therapy including RFA could be used for decompensated liver cirrhosis (Kim et al, 2006a) and it is possible that it might be beneficial in special circumstances, such as when minute growth of the tumour immediately results in the occlusion of major critical vessels.

Several studies have addressed the characters of HCC with decompensated cirrhosis (Nagasue et al, 1999; Ueno et al, 2002; Toyoda et al, 2005). Ueno et al (2002) reported that high albumin, lack of oesophageal varices, small tumour, single tumour, and low AFP were survival factors for HCC patients with decompensated liver cirrhosis. The study included many Child B cirrhosis patients (over 85%); however, the results were quite similar to our data with Child C cirrhosis. Toyoda et al (2005) reported risk factors for HCC patients with Child C cirrhosis and beneficial effect of treatment; however, the study included old cases and details of the treatment were not described. Regarding therapies, BSC was recommended for the treatment of HCC with decompensated cirrhosis, except in transplantation-eligible cases, by the algorithms of HCC treatment demonstrated by groups in Europe and Japan (Bruix et al, 2001; Llovet, 2005; Makuuchi and Kokudo, 2006), while there are several reports indicating the usefulness or safety of operation, RFA, and TACE for patients with decompensated liver cirrhosis (Nagasue et al, 1999; Ueno et al, 2002; Kim et al, 2006a). Prospective randomised study is the best method to know the benefit of these therapies for HCC patients with Child C cirrhosis; however, it is ethically difficult now because no clear evidence of the beneficial effect of active treatments was reported and most of the guidelines for the treatment of HCC did not recommend these therapies except transplantation. Our study was a retrospective cohort study, the patient groups were heterogeneous and the number of patients in each arm was quite limited; however, we clearly indicates the possibility of adopting TACE for the treatment of HCC in patients with Child C cirrhosis by both multivariate Cox proportional hazard model and propensity score-matched analyses.

Recently, improvement of liver function in patients with decompensated liver cirrhosis by anti-hepatitis virus therapy such as lamivudine or adefovir dipivoxil was reported (Hiraoka et al,

2005; Takamura *et al*, 2007). Adoption of these anti-viral therapies can reduce patient mortality from liver failure so that the treatment effect of local ablation therapy may improve, resulting in increased candidates for active treatment of HCC with Child C cirrhosis.

In this study, we demonstrated that tumour factors as well as background liver factors were risk factors even in HCC patients with Child C cirrhosis, and that TACE can be effective in a very selected group of patients. A randomised controlled study is needed to expand the eligible criteria for active treatment.

REFERENCES

- Adams PC, Arthur MJ, Boyer TD, DeLeve LD, Di Bisceglie AM, Hall M, Levin TR, Provenzale D, Seeff L (2004) Screening in liver disease: report of an AASLD clinical workshop. *Hepatology* **39**: 1204–1212
- Bolondi L (2003) Screening for hepatocellular carcinoma in cirrhosis. *J Hepatol* **39**: 1076–1084
- Bruix J, Llovet JM (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. *Hepatology* **35**: 519–524
- Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. *J Hepatol* **35**: 421–430
- Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, Andreone P, Craxi A, Cottone M (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. *Radiology* **224**: 47–54
- Hiraoka A, Michitaka K, Kumagi T, Kurose K, Uehara T, Hirooka M, Yamashita Y, Kubo Y, Miyaoka H, Iuchi H, Okada S, Ohmoto M, Yamamoto K, Horiike N, Onji M (2005) Efficacy of lamivudine therapy for decompensated liver cirrhosis due to hepatitis B virus with or without hepatocellular carcinoma. *Oncol Rep* **13**: 1159–1163
- Honda H, Ochiai K, Adachi E, Yasumori K, Hayashi T, Kawashima A, Fukuya T, Gibo M, Matsumata T, Tsuneyoshi M, Masuda K (1993) Hepatocellular carcinoma: correlation of CT, angiographic, and histopathologic findings. *Radiology* **189**: 857–862
- Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, Monden M, Kudo M (2007) Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. *Hepatol Res* **37**: 676–691
- Kim YK, Kim CS, Chung GH, Han YM, Lee SY, Jin GY, Lee JM (2006a) Radiofrequency ablation of hepatocellular carcinoma in patients with decompensated cirrhosis: evaluation of therapeutic efficacy and safety. *AJR Am J Roentgenol* **186**: S261–S268
- Kim YS, Rhim H, Cho OK, Koh BH, Kim Y (2006b) Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: analysis of the pattern and risk factors. *Eur J Radiol* **59**: 432–441
- Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC (2005) Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. *Gut* **54**: 1151–1156
- Llovet JM (2005) Updated treatment approach to hepatocellular carcinoma. *J Gastroenterol* **40**: 225–235
- Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. *Lancet* **362**: 1907–1917
- Makuuchi M, Kokudo N (2006) Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. *World J Gastroenterol* **12**: 828–829
- Nagasue N, Kohno H, Tachibana M, Yamanoi A, Ohmori H, El-Assal ON (1999) Prognostic factors after hepatic resection for hepatocellular carcinoma associated with Child-Turcotte class B and C cirrhosis. *Ann Surg* **229**: 84–90
- Parkin DM (2001) Global cancer statistics in the year 2000. *Lancet Oncol* **2**: 533–543
- Parsons LS, Ovation Research Group (2001) Reducing bias in a propensity score matched-pair sample using greedy matching techniques. In: *Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference*. pp 214–226. Cary: SAS Institute Inc.
- Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg* **60**: 646–649
- Sala M, Forner A, Varela M, Bruix J (2005) Prognostic prediction in patients with hepatocellular carcinoma. *Semin Liver Dis* **25**: 171–180
- Takamura M, Ichida T, Ohkoshi S, Tsubata S, Osaki A, Aoyagi T, Nomoto M, Uehara K, Terada H, Aoyagi Y (2007) Decompensated lamivudine-resistant hepatitis B virus-related cirrhosis treated successfully with adefovir dipivoxil allowing surgery for hepatocellular carcinoma. *Intern Med* **46**: 367–371
- Tateishi R, Shiina S, Yoshida H, Teratani T, Obi S, Yamashiki N, Akamatsu M, Kawabe T, Omata M (2006) Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. *Hepatology* **44**: 1518–1527
- Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Hayashi K, Honda T, Kuzuya T, Nonogaki K, Shimizu J (2005) Impact of tumor factors on the prognosis of patients with advanced cirrhosis (Child-Pugh class C) and hepatocellular carcinoma. *J Gastroenterol Hepatol* **20**: 963–965
- Trevisani F, Cantarini MC, Labate AM, De Notariis S, Rapaccini G, Farinati F, Del Poggio P, Di Nolfo MA, Benvegno L, Zoli M, Borzio F, Bernardi M (2004) Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. *Am J Gastroenterol* **99**: 1470–1476
- Ueno S, Tanabe G, Nuruki K, Oketani M, Komorizono Y, Hokotate H, Fukukura Y, Baba Y, Imamura Y, Aikou T (2002) Prognosis of hepatocellular carcinoma associated with Child class B and C cirrhosis in relation to treatment: a multivariate analysis of 411 patients at a single center. *J Hepatobiliary Pancreat Surg* **9**: 469–477
- United Network for Organ Sharing (2006) Annual report 2006. <http://www.unos.org/data>
- Wong LL, Limm WM, Severino R, Wong LM (2000) Improved survival with screening for hepatocellular carcinoma. *Liver Transpl* **6**: 320–325